IL-10-Inducing Compounds for IL-6-Sparing Immune Cell Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for immune-mediated diseases focus on suppressing immunity and inflammation but fail to restore dominant immune regulation, leading to treatment resistance and relapse, and do not improve patient quality of life or reduce side effects.
Innovation Solution
Development of a compound that induces the production of interleukin-10 (IL-10) by immune cells, particularly B cells, T cells, and myeloid cells, using specific activation pathways, to generate IL-10-producing immune cells for adoptive cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If immunosuppressive drugs are used to suppress immunity and inflammation, then inflammation is reduced, but treatment resistance and relapse occur due to failure to restore dominant immune regulation
Solution Approach 1:
Instead of suppressing the immune system as conventionally done, the invention inverts the approach by actively restoring and enhancing dominant immune regulation through IL-10 production. The compound shifts the immune response from suppression to restoration of regulatory function, addressing the root cause of treatment failure while reducing inflammation.
Solution Approach 2:
The invention utilizes feedback mechanisms by inducing IL-10 production from immune cells, which then provides regulatory feedback to restore dominant immune regulation. This self-regulating feedback loop ensures sustained treatment effectiveness and prevents relapse by continuously maintaining immune balance.
2Object-affected harmful factors
If cytokine blockers are used to inhibit cytokine signaling, then immune response is suppressed, but quality of life does not improve and side effects persist
Solution Approach 1:
The invention enables the immune system to self-regulate by inducing endogenous IL-10 production from immune cells. This self-service mechanism eliminates the need for continuous external cytokine blocking, allowing the body to naturally maintain immune balance and improve quality of life while reducing side effects.
Solution Approach 2:
The compound induces a parameter change in immune cell function, specifically increasing IL-10 production capacity. This fundamental change in immune cell behavior shifts the system from requiring external suppression to achieving internal regulation, improving patient outcomes and quality of life.
3Object-affected harmful factors
If transient depletion of leukocyte subsets is used, then immune-mediated disease is suppressed, but relapse occurs upon treatment cessation due to lack of sustained regulation
Solution Approach 1:
The compound performs preliminary action by inducing IL-10 production before disease relapse can occur. This proactive approach establishes sustained immune regulation in advance, allowing treatment to be maintained at lower intensity or longer duration without causing relapse, thereby improving overall treatment duration and effectiveness.
Data Source
AI summary
The present invention relates to a compound of formula (I) for its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.